03/29/2026
The lipid-lowering therapy evolocumab reduces the risk of adverse cardiovascular events in high-risk patients who have diabetes but no known significant atherosclerosis, a secondary analysis of the VESALIUS-CV trial shows. Read more from ACC 2026 on CRTonline.
The lipid-lowering therapy evolocumab reduces the risk of adverse cardiovascular events in high-risk patients who have diabetes but no known significant atherosclerosis, a secondary analysis of the VE